Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849313 | 0.87 | BCHE (0.48) | L3MBTL1MEN1KMT2ABRD4GAA | |
| SCHEMBL2845744 | 0.84 | BRD4 (0.45) | L3MBTL1MEN1KMT2ARAB9ABRD4 | |
| SCHEMBL2838329 | 0.80 | BCHE (0.48) | L3MBTL1MEN1KMT2ABRD4GAA | |
| SCHEMBL21066545 | 0.80 | KMT2A (0.52) | L3MBTL1MEN1KMT2ANPC1EPHX2 | |
| SCHEMBL3120956 | 0.78 | CTNNB1 (0.51) | MEN1KMT2ANPC1RAB9ABRD4 | |
| SCHEMBL3285536 | 0.78 | ADORA2A (0.46) | L3MBTL1MEN1KMT2ANPC1EPHX2 | |
| SCHEMBL7652554 | 0.78 | NPC1 (0.58) | L3MBTL1MEN1KMT2ANPC1EPHX2 | |
| SCHEMBL2846431 | 0.77 | STK17B (0.45) | L3MBTL1MEN1KMT2ABRD4GAA | |
| SCHEMBL13326022 | 0.77 | ADORA2A (0.47) | L3MBTL1MEN1KMT2ANPC1EPHX2 | |
| SCHEMBL8757522 | 0.75 | GLA (0.67) | KMT2ANPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8481734-B2 | Pyrazine derivatives and uses thereof, including in medical imaging and visualization applications | MEDIBEACON DEVELOPMENT LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | MALLINCKRODT INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | DPYD, DHPS, DHX15 | L3MBTL1 4744/4885MEN1 2228/4885KMT2A 1384/4885 |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | DPYD, PRDX5, NOX5 | L3MBTL1 4336/4885MEN1 4222/4885KMT2A 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.